MedPath

Merck, Inc.

🇵🇭Philippines
Ownership
Subsidiary
Employees
-
Market Cap
$295.3B
Website
http://www.merck.ph
Clinical Trials
Related News

Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: 10 mg MK-0941 OCT (before meal)
Drug: 10 mg MK-0941 DFC (fasted)
Drug: 10 mg MK-0941 OCT (fasted)
Drug: 10 mg MK-0941 OCT (after meal)
First Posted Date
2007-12-04
Last Posted Date
2015-03-23
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
18
Registration Number
NCT00567112

Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)

Phase 3
Completed
Conditions
Mumps
Rubella
Varicella
Measles
Interventions
Biological: ProQuad® manufactured with recombinant Human Albumin (rHA)
First Posted Date
2007-12-03
Last Posted Date
2018-01-30
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1620
Registration Number
NCT00566527

A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet

Phase 2
Completed
Conditions
Hyperlipidemia
Interventions
Drug: simvastatin 20 mg/ezetimibe
First Posted Date
2007-12-03
Last Posted Date
2007-12-03
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
58
Registration Number
NCT00566267

Tolerability and Efficacy of Ibuprofen 800 mg in a Walking Model of Osteoarthritis Pain (0000-057)

Phase 1
Completed
Conditions
Osteoarthritis, Knee
Interventions
Drug: Placebo
Drug: ibuprofen
First Posted Date
2007-11-29
Last Posted Date
2015-04-10
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
33
Registration Number
NCT00565084

A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)

Phase 1
Completed
Conditions
Hyperlipidemia
Hypercholesterolemia
First Posted Date
2007-11-29
Last Posted Date
2015-02-25
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
50
Registration Number
NCT00565292

A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)

Phase 1
Completed
Conditions
Ambulatory Blood Pressure
First Posted Date
2007-11-29
Last Posted Date
2015-02-27
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
22
Registration Number
NCT00565006

Safety and Efficacy Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis (P08648)

First Posted Date
2007-11-28
Last Posted Date
2017-03-24
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
798
Registration Number
NCT00564421

Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers

Phase 4
Completed
Conditions
Bacterial Infections
Eye Infections
Interventions
Drug: Moxifloxacin
Drug: Azithromycin
First Posted Date
2007-11-28
Last Posted Date
2011-09-22
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
48
Registration Number
NCT00564447

Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)

Phase 3
Completed
Conditions
Insomnia
Sleep Initiation and Maintenance Disorders
Mental Disorders
Dyssomnias
Sleep Disorders
Interventions
Drug: Esmirtazapine
Drug: Placebo
First Posted Date
2007-11-21
Last Posted Date
2018-10-03
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
538
Registration Number
NCT00561821

A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)

Phase 3
Completed
Conditions
Dyssomnias
Sleep Disorders
Sleep Disorder, Intrinsic
Mental Disorder
Sleep Initiation and Maintenance Disorder; Elderly
Interventions
Drug: Esmirtazapine
First Posted Date
2007-11-21
Last Posted Date
2021-01-27
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
259
Registration Number
NCT00561574
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy